CAMBRIDGE, Mass.--(BUSINESS WIRE)--Agilis Biotherapeutics, LLC (Agilis), a biotechnology company advancing innovative DNA therapeutics for rare genetic diseases that affect the central nervous system (CNS), announced today that the Company has been chosen as one of the “Top Projects to Watch” at the 10th Annual Therapeutic Area Partnerships (TAP) Conference, taking place November 19-21, 2015, in Boston, MA. Additionally, Dr. Mark Pykett, President and CEO of Agilis, presented in the Advanced Therapies session of the conference and participated as a panelist at the gene therapy roundtable.
